Toujeo Versus NPH Self-titration Study

Inclusion criteria

• Type 2 diabetic suboptimally controlled on their previous antidiabetic treatment

• 18 ≤ age ≤ 75
• Stable dose of oral antidiabetic treatment for > 8 weeks
• The number of OADs that the patients used should be "3" or less
• HbA1c level > 7.0% and < 10%
• Fasting plasma glucose > 8mmol/L and <15mmol
• BMI < 40 kg/m2
• Patient who is capable and willing to perform regular SMBG
• Patient who is capable and willing for insulin injection
• Confirmed written consent
• Insulin naïve

Exclusion criteria

• Participation in a clinical trial with any investigational drug used with curative intent and within 30 days prior to study entry
• Patient known to have hypoglycaemia unawareness or recurrent major hypoglycaemia
• Any product containing prandial insulin
• Concomitant medication known to interface with glucose metabolism (such as systematic steroids)
• Change in dose of non-insulin anti-diabetic treatment or initiation of new anti-diabetic medications in the last 8 weeks prior to screening
• Patients treated with steroid or nonsteroidal anti-inflammatory drugs
• Patient who had experienced an acute concurrent illness during the 3-month period before the investigation
• Patient with hepatic disease and end-stage renal disease
• Patients unable to comply with follow-up visits
• Pregnant or breastfeeding women